Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism gclc expression decreased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism gpx1a expression decreased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism gstp1.2 expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 1
from Mills et al., 2019
|
whole organism sod1 expression decreased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism gpx1a expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
whole organism gpx1a expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism sod2 expression decreased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism gclc expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism hmox1a expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism nqo1 expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
whole organism gstp1.2 expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
whole organism decreased life span, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
standard conditions
|
text only
from Mills et al., 2019
|
whole organism gstp1.2 expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
control
|
Fig. 1,
Fig. 2
from Mills et al., 2019
|
whole organism viability, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
standard conditions
|
Table 1
from Mills et al., 2019
|
whole organism prdx1 expression increased amount, abnormal
|
nfe2l2adw213/dw213 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism gstp1.2 expression increased amount, abnormal
|
nfe2l2adw214a/dw214a (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 1
from Mills et al., 2019
|
whole organism decreased life span, abnormal
|
nfe2l2adw214a/dw214a (EKW)
|
standard conditions
|
text only
from Mills et al., 2019
|
whole organism gstp1.2 expression increased amount, abnormal
|
nfe2l2adw214a/dw214a (EKW)
|
control
|
Fig. 1
from Mills et al., 2019
|
whole organism dead, abnormal
|
nfe2l2adw214a/dw214a (EKW)
|
standard conditions
|
text only
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw210/w210 (EKW)
|
control
|
Fig. 1
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw210/w210 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 1
from Mills et al., 2019
|
response to toxic substance process quality, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism gclc expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism nqo1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
response to hydroperoxide process quality, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism gpx1a expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism dead, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism sod1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism sod1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
control
|
Fig. 1,
Fig. 2
from Mills et al., 2019
|
whole organism sod2 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism hmox1a expression increased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism dead, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism nqo1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: (-)-carvone
|
Fig. 2
from Mills et al., 2019
|
whole organism hmox1a expression increased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
whole organism hmox1a expression increased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 1
from Mills et al., 2019
|
whole organism prdx1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
control
|
Fig. 2
from Mills et al., 2019
|
whole organism sod1 expression decreased amount, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 2
from Mills et al., 2019
|
response to hydroperoxide process quality, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: cumene hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
response to toxic substance process quality, abnormal
|
nfe2l2aw211/w211 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw212/w212 (EKW)
|
control
|
Fig. 1
from Mills et al., 2019
|
whole organism gstp1.2 expression decreased amount, abnormal
|
nfe2l2aw212/w212 (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 1
from Mills et al., 2019
|
whole organism life span, ameliorated
|
nfe2l2adw213/+ (EKW)
|
chemical treatment by environment: tert-butyl hydroperoxide
|
Fig. 3
from Mills et al., 2019
|
whole organism decreased length, abnormal
|
nfe2l2adw214a/+ (EKW)
|
standard conditions
|
Table 1
from Mills et al., 2019
|
hepatocyte necrotic, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 6
from Yamashita et al., 2018
|
whole organism gstp1.2 expression decreased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 7
from Yamashita et al., 2018
|
hepatocyte vacuolated, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 6
from Yamashita et al., 2018
|
whole organism nfe2l2b expression increased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 7
from Yamashita et al., 2018
|
whole organism dead, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: hydrogen peroxide
|
Fig. 3
from Yamashita et al., 2018
|
whole organism nfe2l2b expression increased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: hydrogen peroxide
|
Fig. 4
from Yamashita et al., 2018
|
whole organism keap1b expression decreased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 7
from Yamashita et al., 2018
|
whole organism gclc expression decreased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
control
|
Fig. 4
from Yamashita et al., 2018
|
heart contraction process quality, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: doxorubicin
|
Fig. 8
from Yamashita et al., 2018
|
whole organism dead, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: sulforaphane, chemical treatment by environment: hydrogen peroxide
|
Fig. 3
from Yamashita et al., 2018
|
liver decreased size, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: paracetamol
|
Fig. 5
from Yamashita et al., 2018
|
heart contraction decreased rate, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: doxorubicin
|
Fig. 8
from Yamashita et al., 2018
|
whole organism gstp1.2 expression decreased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
control
|
Fig. 7
from Yamashita et al., 2018
|
whole organism gclc expression decreased amount, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: hydrogen peroxide
|
Fig. 4
from Yamashita et al., 2018
|
whole organism decreased life span, abnormal
|
mitfab692/b692; nfe2l2azf3103/zf3103
|
chemical treatment by environment: hydrogen peroxide
|
Fig. 2
from Yamashita et al., 2018
|